TIGIT and neoplasm: Consistent with our findings, emerging experimental studies have also shown that immuno-modulatory antibody combinations targeting three checkpoints, e.g., anti-CTLA4/PD-L1 (BsAb) with anti-TIGIT (mAb) in Huang et al. or the tri-specific anti-PD-L1/TIGIT/LAG3 therapeutic in Yang et al., can deliver more pronounced T cell activation and anti-tumor potency compared to targeting only two checkpoints (e.g., by a BsAb) (Yang et al., 2023; Huang et al., 2022).